Suven Life Sciences Limited (NSE:SUVEN)
India · Delayed Price · Currency is INR 235.20
+2.95 (1.27%)
Aug 14, 2025, 3:29 PM IST
Suven Life Sciences Revenue
Suven Life Sciences had revenue of 18.67M INR in the quarter ending June 30, 2025, with 85.56% growth. This brings the company's revenue in the last twelve months to 75.17M, down -15.56% year-over-year. In the fiscal year ending March 31, 2025, Suven Life Sciences had annual revenue of 66.56M, down -43.08%.
Revenue (ttm)
75.17M
Revenue Growth
-15.56%
P/S Ratio
686.53
Revenue / Employee
544.67K
Employees
138
Market Cap
51.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 66.56M | -50.37M | -43.08% |
| Mar 31, 2024 | 116.93M | -19.02M | -13.99% |
| Mar 31, 2023 | 135.95M | 16.44M | 13.76% |
| Mar 31, 2022 | 119.51M | -21.23M | -15.08% |
| Mar 31, 2021 | 140.73M | -6.32M | -4.30% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 537.77B |
| Divi's Laboratories | 96.52B |
| Cipla | 274.80B |
| Apollo Hospitals Enterprise | 225.51B |
| Mankind Pharma | 129.10B |
| Zydus Lifesciences | 236.08B |
| Fortis Healthcare | 80.94B |
| Alkem Laboratories | 133.04B |
Suven Life Sciences News
- 7 months ago - Suven Life Sciences shares surge over 8% after clinical trial update - Business Upturn
- 7 months ago - Suven Life Sciences initiates Phase-1 clinical trial for SUVN-I6107 - Business Upturn